Table 1. Characteristics of the evaluated patients.

Pt. no.	Sex	Age (years)	Prior tumour therapy (best response)	Karnofski (%)	Clinical status at start	Metastasis	Number of infusions	Response after first cycle	Survival (months; until January 2002)
1	M	68	IFN+Vinbl (PD)	90–100	PD	Adrenal	12	PD	6
2	F	45	IFN+Vinbl (PD)	70	PD	Lung and liver	4	PD	2
3	F	75	None	80	PD	Lung	12	PD	4
4	M	51	None	80	PD	Lung, liver and LN	11	PD	3
5	F	77	None	90	PD	Lung	5	PD	2
6a	M	66	IFN+Vinbl (SD)	80	PD	Lung and liver	20	SD	18+
			IFN+Vinbl (PD)
			5FU+CF (PD)
7	F	58	Radiation (PD)	90–100	PD	Lung	12	PD	18+
8	M	77	IFN+Vinbl	80	PD	Lung and bone	4	PD	Date unknown
			5FU+CF
9a	M	68	IFN+Vinbl (SD)	90–100	PD	Lung, pleura, adrenal	20	SD	18+
			5FU+CF (SD)
10	M	69	IL-2/IFN/5FU (SD)	90–100	PD	Lung and liver	12	PD	18+
			IL-2/IFN/5FU red (PD)
11	M	66	None	90–100	PD	Lung and LN	12	PD	17
12	F	67	None	90–100	UN	Liver, spleen and LN	12	PD	18+
13	F	64	IFN+Vinbl (PD)	90–100	PD	Lung and liver	11	PD	4
14	M	72	None	90–100	PD	Lung	7	PD	1
15	M	51	IFN+Vinbl (PD)	90–100	PD	Lung, LN, pancreas	12	PD	17+
16	M	54	IFN+Vinbl (PD)	90–100	PD	LN, contralateral kidney and psoas muscle	12	SD	17+
			IFN+cis-RA (PD)
			5FU+CF (PD)
17	M	67	IFN+Vinbl	80	PD	Lung	5	PD	7
18	M	50	IFN (PD)	90–100	PD	Lung	12	PD	9
19	M	43	None	90–100	PD	Lung and LN	12	PD	8
20	F	60	None	80	UN	LN	12	PD	11
21a	M	69	None	90–100	UN	Lung and LN	20	SD	16+
22a	M	70	None	90–100	UN	LN	20	SD	13
23a	M	61	None	80	PD	Lung, LN and Liver	20	SD	16+
24a	M	56	IL-2 (SD)	90–100	PD	LN	20	SD	15+
			DC vaccination (SD)
25a	F	52	IFN+cis-RA (CR)	90–100	PD	Other kidney	20	SD	15+
26	M	69	IL-2/IFN/5FU (PD)	80	PD	Lung and LN	12	PD	15+
27a	M	57	IL-2/IFN/5FU (PR)	90–100	UN	Lung	20	SD	15+
28a	F	76	None	90–100	PD	Lung and adrenal	20	SD	14
29	M	66	IL-2/IFN/5FU (SD)	80	PD	Lung and LN	12	PD	15+
			IL-2 inhalation (PD)
30	F	65	IL-2/IFN/5FU (PD)	90–100	PD	Lung and LN	12	PD	14+
			Toremifene+Vinbl (PD)
31	F	70	IFN+Vinbl (PR)	90–100	PD	Lung	12	PD	14+
			IFN+Vinbl (PD)
			IFN+Vinbl (PD)
32	M	76	None	90–100	PD	Lung	12	PD	14+
33	M	71	None	80	PD	LN and pleura	12	PD	14+
34	M	57	Vaccination (PD)	90–100	PD	Lung	12	PD	7
35	M	67	IFN+cis-RA (SD)	90–100	PD	Lung and LN	10	PD	5
36a	F	73	None	80	PD	Lung	20	SD	13+

^aPatients who received extended treatment.

Sex: M=male, F=female; response: PD=progressive disease, SD=stable disease, PR=partial response, CR=complete response, UN=unknown; metastasis: LN=lymphnode; prior treatment: IFN=interferon-alpha, Vinbl=vinblastine, 5FU=5-fluorouracil, CF=calcium folinate, IL-2=interleukin-2, cis-RA=cis-retinoic acid, DC=dendritic cell.